PASSAGE BIO
Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvania and its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach.
PASSAGE BIO
Industry:
Biotechnology Health Care Therapeutics Wellness
Founded:
2018-01-01
Address:
Philadelphia, Pennsylvania, United States
Country:
United States
Website Url:
http://www.passagebio.com
Total Employee:
51+
Status:
Active
Contact:
267-866-0311
Email Addresses:
[email protected]
Total Funding:
379.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Google Tag Manager Content Delivery Network Google Universal Analytics IPv6
Similar Organizations
Abalone Bio
Abalone Bio is an early stage biotech start-up that develops antibody drugs for the treatment of diseases.
amcure
amcure is a clinical-stage company develops peptide-based compounds for the treatment of highly metastatic forms of squamous cancer.
Amicus Therapeutics
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
AppliedVR
AppliedVR offers virtual reality-based therapeutic treatments that address the complexity of chronic pain.
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company that develops novel treatments for inherited forms of blindness.
Aurinia Pharmaceuticals
Aurinia develops and commercializes therapies to treat targeted patient populations suffering from serious auto-immune diseases.
BIOMx
BIOMx is a microbiome therapeutics company developing synbio phage therapies to eradicate harmful bacteria in chronic diseases.
Bionure
Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of rare ophthalmology diseases.
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Circular Genomics
Circular Genomics is a biotechnology and genomics company that develops RNA-based diagnostics for neurological diseases.
Contessa
Contessa operates Home Recovery Care, combining all the essential elements of inpatient hospital care in the comfort of patients’ homes.
Edifice Health
Edifice Health is a immunological health and personalized nutrition company offering a novel metric of inflammatory health.
Enable My Child
Enable My Child is a high-quality solution in pediatric mental health, speech, physical, and occupational therapy leveraging AI.
Reunion Neuroscience
Field Trip Health, Inc. providing simple, evidence-based therapies for healing and heightening engagement with the world.
Gridiron BioNutrients
Gridiron BioNutrients is an emerging company in the rapidly-growing CBD hemp-oil industry.
Humabiologics
Humabiologics is a regenerative medicine startup to address the gap between the gift of donated human tissues and researchers.
Hurdle
Hurdle is an app that helps people find healthy ways to manage stress from all parts of life and create routines that promote wellness.
Inspire Medical Systems
Inspire Medical Systems develops implantable therapeutic devices for the treatment of obstructive sleep apnea.
IsoPlexis
IsoPlexis is a life science technology company that develops a single-cell detection system identifying patient immune responses.
Magnolia NeuroSciences
Magnolia NeuroSciences discovers and develops drug-like small molecule therapeutics for the prevention of neuronal cell death.
Modern Health
Modern Health is a mental well-being platform for innovative companies offering therapy, coaching, and self-guided courses all in one app.
Nanobiotix
Nanobiotix is a nanomedicine company developing novel therapeutics for the local treatment of cancer.
NanoVibronix
NanoVibronix is a medical device company employing its proprietary therapeutic ultrasound technologies to develop portable devices.
Notitia Biotechnologies
Notitia Biotechnologies develops a biotechnology platform that uses a new method for microbiome data analysis and discovery.
Numinus
Numinus utilizes psychedelic-assisted psychotherapy methods to bring holistic healthcare to patients.
PatientPing
PatientPing is a care coordination data and software company.
Pure Scientific Technologies
Pure Scientific Technologies is a medical device startup company that develops a new patent-pending drug delivery system.
Qpex Biopharma
Qpex Biopharma develops a pipeline of agents addressing critical needs for the treatment of infectious diseases.
Restore Hyper Wellness
Restore is The Hyper Wellness® Company that helps you feel better and do more of what you love with its proactive health & wellness services
Reulay, Inc
Reulay leverages machine learning and mixed reality treatments to reduce stress and anxiety disorders associated with chronic disease
SNIPR Biome
SNIPR Biome is a operator of a discovery stage biotech company intended to revolutionize the treatment of microbial diseases.
Taysha Gene Therapies
Taysha Gene Therapies develops treatments to eradicate severe and life-threatening monogenic diseases of the central nervous system.
Two Chairs
Two Chairs is a behavioral health company that operates a mental health therapy platform to offer in-person psychotherapy.
UDAMO
Udamo is a digital therapeutics company focusing on the automation of Cognitive Behavioural Therapy (CBT) interventions
Sapphire Digital
Sapphire Digital is a full omnichannel digital engagement and shopping platform for consumers, employers.
Voyager Therapeutics
Voyager Therapeutics is a biotechnology company specializing in gene therapy and neurology.
Welldoc
Welldoc is a health care technology company that develops solutions to transform the management of chronic disease.
Urgent Team Holdings, Inc.
Urgent Team operates centers providing urgent and primary healthcare services and preventative wellness services.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Lilly Asia Ventures
Lilly Asia Ventures investment in Series B - Passage Bio
Highline Capital Management
Highline Capital Management investment in Series B - Passage Bio
Sphera Funds Management
Sphera Funds Management investment in Series B - Passage Bio
Versant Ventures
Versant Ventures investment in Series B - Passage Bio
New Leaf Venture Partners
New Leaf Venture Partners investment in Series B - Passage Bio
Boxer Capital
Boxer Capital investment in Series B - Passage Bio
Len Blavatnik
Len Blavatnik investment in Series B - Passage Bio
Logos Capital
Logos Capital investment in Series B - Passage Bio
OrbiMed
OrbiMed investment in Series B - Passage Bio
Frazier Healthcare Partners
Frazier Healthcare Partners investment in Series B - Passage Bio
Key Employee Changes
| Date | New article |
|---|---|
| 2020-01-28 | Passage Bio Appoints Deerfield Management’s Bruce Goldsmith as CEO |
Official Site Inspections
http://www.passagebio.com Semrush global rank: 6.39 M Semrush visits lastest month: 1.06 K
Unable to get host informations!!!
More informations about "Passage Bio"
Passage Bio - Crunchbase Company Profile & Funding
Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases. See details»
Passage Bio, Inc. - Our Company - Our Team
Passage Bio is a genetic medicines company led by an executive team with deep experience in rare diseases, CNS disorders, and gene therapy. See details»
Passage Bio Inc Company Profile - Passage Bio Inc Overview
Up-to-date Passage Bio Inc company overview including funding information, company profile, key statistics, peer comparison and more. See details»
Passage Bio - 2025 Company Profile - Tracxn
Jun 11, 2025 Passage Bio - Developer of gene therapies for CNS rare diseases. Public Company. Raised a total funding of $226M over 3 rounds from 12 investors. See details»
Passage Bio Inc, PASG:NAQ profile - FT.com
Jun 30, 2025 Passage Bio Inc (PASG:NAQ) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more. See details»
Passage Bio - Craft
Oct 29, 2024 Passage Bio has 1 employees at their 1 location. See insights on Passage Bio including office locations, competitors, revenue, financials, executives, subsidiaries and more … See details»
Passage Bio - VentureRadar
"Passage Bio has a focused mission to provide life-transforming therapies for patients with CNS disorders. Our next-generation science uses the leading platform for in vivo treatment of … See details»
Passage Bio Overview | SignalHire Company Profile
Total funding of the company - $441.5M. To connect with Passage Bio employee register on SignalHire. Organization Website passagebio.com Social Links Phone Number 1-267- 866 … See details»
Passage Bio, Inc. - Our Company - Who We …
Who We Are At Passage Bio, our mission is to improve the lives of patients with neurodegenerative diseases by delivering genetic medicines that will permanently redefine the course of their … See details»
Passage Bio Welcomes Tom Kassberg to Board of Directors
Sep 10, 2024 "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission forward during this critical … See details»
Passage Bio, Inc. - Pipeline - Overview
Read more about Passage Bio’s gene therapy pipeline for rare disorders of the CNS, including 3 therapies in Phase 1/2 clinical trials. See details»
Passage Bio, Inc. - Passage Bio Announces Leadership Transition
Jun 1, 2022 Bruce Goldsmith, Ph.D. to step down as president and chief executive officer and member of board of directors, will serve as a strategic advisor for a transition period Edgar B. … See details»
Passage Bio, Inc. - Corporate Presentation - October 2021
Oct 4, 2021 New hope for people with previously untreatable central nervous system disorders. Learn more about CNS diseases and our commitment to transform the lives of the people … See details»
Passage Bio, Inc. - Investors and News - Overview
Overview Passage Bio is a clinical stage genetic medicines company on a mission to improve the lives of patients with neurodegenerative diseases. Our primary focus is the development and … See details»
Passage Bio Announces 1-for-20 Reverse Stock Split
1 day ago PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) - Passage Bio, Inc. (“ Passage Bio ” or the “ Company ”) (NASDAQ: PASG), a clinical-stage genetic medicines company … See details»
Passage Bio Announces Recipient of Third Annual Tachi Yamada ...
PHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE) - Passage Bio, Inc. (Nasdaq: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with … See details»
Passage Bio Announces 1-for-20 Reverse Stock Split to Regain
1 day ago Passage Bio announces a 1-for-20 reverse stock split effective July 14, 2025, to comply with Nasdaq requirements. See details»
Passage Bio Announces 1-for-20 Reverse Stock Split
1 day ago The reverse stock split was approved by Passage Bio’s stockholders, at the Company’s 2025 annual meeting of stockholders held on May 28, 2025, to be effected at the … See details»
Passage Bio | Philadelphia PA - Facebook
PASSAGEBIO.COM Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference … See details»
Passage Bio to Participate in Upcoming Investor Conferences
PHILADELPHIA, Aug. 06, 2024 (GLOBE NEWSWIRE) - Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with … See details»